van den Dries Lennert, Claassen Mark A A, Groothuismink Zwier M A, van Gorp Eric, Boonstra Andre
Erasmus Medical Centre, Department of Viroscience, Rotterdam, The Netherlands.
Erasmus Medical Centre, Department of Infectious Diseases, Rotterdam, The Netherlands; Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands; Rijnstate Hospital, Department of Internal Medicine, Infectious Diseases Unit, Arnhem, The Netherlands.
Virology. 2017 Sep;509:133-139. doi: 10.1016/j.virol.2017.06.014. Epub 2017 Jun 20.
Sustained immune activation during chronic HIV infection is considered to augment co-morbidity and mortality. Effective combination antiretroviral therapy (cART) has shown to dampen immune activation especially during the first year cART, but the effects of long-term cART in patients without major comorbidities remains under-investigated. We performed a comprehensive analysis including cellular, intracellular and plasma biomarkers to study the effect of cART on immune parameters in 5 groups of 10 HIV patients. All patients were without major co-morbidities and grouped based on cART duration (0, 1, 3, 5, and 10 years). We included 10 matched healthy controls for comparison. Our data show that after the first year of cART, no additional effect on the level of inflammatory markers is observed in HIV infected patients without major co morbidities. Residual immune activation status in well-treated HIV-infection is similar to levels observed in healthy controls.
慢性HIV感染期间持续的免疫激活被认为会增加合并症和死亡率。有效的联合抗逆转录病毒疗法（cART）已显示可抑制免疫激活，尤其是在cART治疗的第一年，但长期cART对无重大合并症患者的影响仍未得到充分研究。我们进行了一项综合分析，包括细胞、细胞内和血浆生物标志物，以研究cART对5组每组10名HIV患者免疫参数的影响。所有患者均无重大合并症，并根据cART持续时间（0、1、3、5和10年）分组。我们纳入了10名匹配的健康对照进行比较。我们的数据显示，在cART治疗的第一年之后，在无重大合并症的HIV感染患者中未观察到对炎症标志物水平有额外影响。经过良好治疗的HIV感染患者的残余免疫激活状态与健康对照中观察到的水平相似。
